New Zealand markets closed

NRx Pharmaceuticals, Inc. (NRXP)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.2750+0.0074 (+2.77%)
As of 10:42AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 22.28M
Enterprise value 20.00M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)6.95
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.51

Trading information

Stock price history

Beta (5Y monthly) 0.85
52-week change 3-63.78%
S&P500 52-week change 319.92%
52-week high 31.5400
52-week low 30.2210
50-day moving average 30.3104
200-day moving average 30.6819

Share statistics

Avg vol (3-month) 31.41M
Avg vol (10-day) 31M
Shares outstanding 583.24M
Implied shares outstanding 683.24M
Float 846.36M
% held by insiders 136.03%
% held by institutions 14.23%
Shares short (14 Sept 2023) 41.46M
Short ratio (14 Sept 2023) 40.48
Short % of float (14 Sept 2023) 42.66%
Short % of shares outstanding (14 Sept 2023) 41.75%
Shares short (prior month 14 Aug 2023) 4801.04k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Jun 2023


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-87.10%
Return on equity (ttm)-346.70%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
Net income avi to common (ttm)-39.08M
Diluted EPS (ttm)-0.6100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)14.97M
Total cash per share (mrq)0.19
Total debt (mrq)12.69M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.88
Book value per share (mrq)-0.04

Cash flow statement

Operating cash flow (ttm)-28.48M
Levered free cash flow (ttm)-14.32M